Remove Aortic Remove Reimbursement Remove Stenosis
article thumbnail

Cassling Partner Echo IQ Secures FDA Clearance for EchoSolv AS

Cassling

510(k) clearance secured from FDA allows for EIQ’s AI-enabled solution, EchoSolv AS, to be marketed and sold in the USA Clearance marks a major milestone and will allow for rapid commercial scale-up EIQ is in advanced discussions with a range of US healthcare providers around the potential uptake of EchoSolv AS Working alongside US consultancy to obtain (..)

article thumbnail

Supercharging the ECG: AI set to Revolutionize the Diagnostic Cardiology Market

DAIC

Inevitably, given its fledgling status, regulation and reimbursement is still playing catch-up, though 2023 saw some important developments in this regard. Research is also underway into algorithms for the diagnosis of Aortic Stenosis and Myocarditis and should be ready for commercialization in the next 18 – 36 months.

AFIB 105